Pramlintide and Breastfeeding

Summary of use during lactation

Pramlintide has a high molecular weight, so it is unlikely to pass into breastmilk in clinically important amounts. It also has a short half-life and it is a peptide that is likely digested in the infant's gastrointestinal tract, so it is unlikely to reach the clinically important levels in infant serum. However, because no information is available on the use of pramlintide during breastfeeding an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Monitor breastfed infants for signs of hypoglycemia such as jitteriness, excessive sleepiness, poor feeding, seizures cyanosis, apnea, or hypothermia. If there is concern, monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with pramlintide.[1]

Drug levels in milk and infant serum

Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information was not found as of the revision date.

Alternative drugs to consider

Acarbose, Glipizide, Glyburide, Insulin, Metformin, Miglitol

References

1. Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med 2005;10:149-59.15701580 PubMed